CVS Health announced on Monday that it will be adding four new members to its board from the hedge fund Glenview Capital Management. This move comes after productive discussions with the activist investor, who had been pushing for changes within the healthcare giant.
The new board members joining CVS Health are Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman. With these additions, the Board now consists of 16 members, bringing in new perspectives and deep industry experience to drive greater financial and operational performance.
Roger Farah, executive chairman of the CVS board, expressed optimism about the collaboration with Glenview, stating that they can deliver greater value to all stakeholders. He emphasized the importance of integrating the businesses to benefit customers, consumers, colleagues, and shareholders.
Despite previous speculation in the media about a potential breakup of CVS, the new CEO, David Joyner, has made it clear that the company is focused on improving its diversified portfolio of businesses. This includes drugstores, outpatient services, primary care clinics, the Caremark pharmacy benefit management company, and Aetna, one of the nation’s largest health insurance companies.
Joyner highlighted CVS’s leading position in the industry, with the best-run pharmacy, a strong PBM, and innovative healthcare delivery assets. He reiterated the company’s commitment to driving innovation and improving the overall customer experience.
The addition of the new board members is seen as a strategic move to further enhance CVS’s focus on executing its strategy to build a world of health around every consumer. Larry Robbins, CEO of Glenview Capital Management, expressed appreciation for the collaborative engagement with the Board and the opportunity to drive long-term value for the company.
In conclusion, the partnership between CVS Health and Glenview Capital Management signifies a shared commitment to strengthening the company and delivering sustainable value through customer-centric offerings, compliance, quality, and optimal capital allocation. The new board members bring a wealth of experience and expertise to the table, positioning CVS for future growth and success in the healthcare industry.
